Breast Cancer Awareness Month: The Newest Treatment Advances to Know About

By Cami Grasher

October marks Breast Cancer Awareness Month, and this year there's genuinely encouraging news behind the pink ribbons. Roughly 322,000 women are expected to be diagnosed with breast cancer this year, but thanks to advances in early detection and treatment, the relative five year survival rate has climbed above 90%. Much of that progress is being driven by a wave of new, more targeted therapies approved just in the past several months. Here's a look at what's new, and why it matters.

The Big Shift: Personalized, Biomarker Driven Treatment

The clearest theme running through 2026's approvals is personalization. Rather than treating breast cancer as a single disease, doctors are increasingly able to match a specific drug to a patient's specific tumor biology, using biomarker tests to guide the decision. This matters because it means fewer patients receiving treatments unlikely to help them, and more patients getting therapies designed around the exact mutation or receptor status driving their particular cancer.

New Approvals for Metastatic and Advanced Breast Cancer

Datroway (datopotamab deruxtecan). Approved in May 2026 for adults with unresectable or metastatic triple negative breast cancer who aren't candidates for immunotherapy. Datroway is an antibody drug conjugate, a newer class of cancer treatment sometimes described as a "guided missile." It attaches to cancer cells and delivers a cell killing drug directly to them, reducing damage to healthy tissue compared to traditional chemotherapy. Triple negative breast cancer has historically had fewer targeted options, so this approval fills a real gap.

Veppanu (vepdegestrant). Approved in May 2026 for advanced or metastatic hormone receptor positive breast cancer, specifically for patients whose tumors have developed an ESR1 mutation, a common way tumors become resistant to standard hormone therapy over time. Veppanu is part of a newer drug class called selective estrogen receptor degraders, and unlike older hormone therapies, it works by binding to the estrogen receptor and signaling the cell to destroy it entirely, rather than simply blocking it. It's taken as a pill, and the FDA also approved a companion blood test, Guardant360 CDx, to identify which patients carry the ESR1 mutation and are likely to benefit.

Camizestrant. Approved in September 2026 under the FDA's accelerated approval program, camizestrant is another oral hormone therapy targeting ESR1 mutations in patients whose cancer has grown resistant to standard treatment. As Acting FDA Commissioner Kyle Diamantas put it at the time, women living with metastatic breast cancer face tumors that continuously evolve to escape treatment, and options like this give doctors another tool to respond as that resistance develops.

Gedatolisib. Approved in July 2026 for ER positive, HER2 negative metastatic breast cancer, based on the VIKTORIA 1 trial led by researchers at Fred Hutchinson Cancer Center. Gedatolisib is a multi targeted kinase inhibitor, meaning it works by disrupting several points along a signaling pathway that cancer cells often hijack to keep growing and resist treatment, rather than targeting just one point of that pathway.

Progress for Early Stage and High Risk Disease

Not all of this year's advances are limited to metastatic disease. Trastuzumab deruxtecan, known as T DXd, was already approved for certain metastatic HER2 positive and HER2 low breast cancers, but two new approvals this year expanded its use into early stage cancer as well. This followed strong results from the DESTINY Breast05 trial, in which patients receiving T DXd after surgery for high risk, residual HER2 positive disease saw a 53% reduction in the risk of disease progression or death compared to a previous standard treatment, along with meaningfully higher three year survival free of invasive disease.

This kind of movement, bringing a therapy proven effective in advanced disease into earlier stage treatment, is one of the more encouraging patterns in recent breast cancer research, since catching and effectively treating disease earlier generally leads to better long term outcomes.

What's Still Being Reviewed

Several additional treatments are moving through the FDA pipeline as of this fall, including newer CDK4 inhibitors, PI3K alpha targeted therapies, and combination approaches pairing multiple targeted drugs together. One trial worth watching, SERENA 6, tested whether switching patients to camizestrant the moment a blood test detects an ESR1 mutation, before scans even show visible tumor growth, could extend the time before disease progresses. Early results showed progression free survival extending to 16 months compared to 9.2 months with standard treatment, though an FDA advisory committee voted against recommending approval for this specific early switching strategy in April 2026, a reminder that even promising results don't guarantee smooth regulatory approval.

What This Means for Patients

The throughline across all of these developments is that breast cancer treatment is becoming less one size fits all. Biomarker testing, whether through tumor tissue or a blood based liquid biopsy, is playing a larger role than ever in determining which drug is likely to work for a given patient, and new drug classes like antibody drug conjugates and next generation hormone therapies are giving doctors options for patients whose cancer has stopped responding to older treatments.

If you or someone you love is navigating a breast cancer diagnosis, this is a reasonable moment to ask your oncologist directly whether biomarker testing has been done, and whether any of these newer treatment classes might be relevant to your specific case. Treatment options are evolving quickly enough that it's worth asking, even if you were told something different even a year or two ago.

This article summarizes recent FDA approvals and research for general educational purposes and isn't medical advice. Treatment decisions should always be made in consultation with an oncologist familiar with your specific diagnosis and health history.